Global Finance News
25 Sep 2026, 18:06
Johnson & Johnson’s TREMFYA Meets Key Endpoints in Phase 4 Axial Psoriatic Arthritis Study
Johnson & Johnson (NYSE: JNJ) said TREMFYA (guselkumab) met the primary and major secondary endpoints in the Phase 4 STAR study evaluating biologic-naïve adults with active psoriatic arthritis and axial involvement. The company said the treatment improved spinal pain, stiffness and other axial symptoms while also reducing MRI-confirmed inflammation.
TREMFYA achieved a significant improvement in the BASDAI disease activity score at Week 24 versus placebo and also met secondary endpoints measuring axial symptoms through ASDAS-CRP and inflammation of the sacroiliac joints by MRI. Johnson & Johnson said the safety profile was consistent with TREMFYA’s established profile in psoriatic arthritis, with no new safety signals identified.
The STAR study enrolled 411 patients and is notable for using MRI-confirmed axial inflammation both for patient selection and for assessing treatment response. Johnson & Johnson said the results strengthen the evidence for TREMFYA in axial psoriatic arthritis, an area where dedicated prospective trials remain limited.
TREMFYA is already approved for active psoriatic arthritis and several other inflammatory diseases, and Johnson & Johnson recently received an FDA label expansion recognizing its ability to inhibit progression of structural joint damage in adults with active PsA. Detailed STAR efficacy and safety data are expected at an upcoming scientific congress.
Johnson & Johnson (NYSE: JNJ) said TREMFYA (guselkumab) met the primary and major secondary endpoints in the Phase 4 STAR study evaluating biologic-naïve adults with active psoriatic arthritis and axial involvement. The company said the treatment improved spinal pain, stiffness and other axial symptoms while also reducing MRI-confirmed inflammation.
TREMFYA achieved a significant improvement in the BASDAI disease activity score at Week 24 versus placebo and also met secondary endpoints measuring axial symptoms through ASDAS-CRP and inflammation of the sacroiliac joints by MRI. Johnson & Johnson said the safety profile was consistent with TREMFYA’s established profile in psoriatic arthritis, with no new safety signals identified.
The STAR study enrolled 411 patients and is notable for using MRI-confirmed axial inflammation both for patient selection and for assessing treatment response. Johnson & Johnson said the results strengthen the evidence for TREMFYA in axial psoriatic arthritis, an area where dedicated prospective trials remain limited.
TREMFYA is already approved for active psoriatic arthritis and several other inflammatory diseases, and Johnson & Johnson recently received an FDA label expansion recognizing its ability to inhibit progression of structural joint damage in adults with active PsA. Detailed STAR efficacy and safety data are expected at an upcoming scientific congress.
